805 related articles for article (PubMed ID: 8644289)
21. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
22. Living related donor kidney transplantation in patients with a positive flow cytometry crossmatch.
Hong JH; Sadeghian M; Sumrani N; Distant DA; Sommer BG; Norin AJ
Transplant Proc; 1996 Jun; 28(3):1614-5. PubMed ID: 8658808
[No Abstract] [Full Text] [Related]
23. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
[No Abstract] [Full Text] [Related]
24. Optimal immunosuppressive clinical regimen in liver transplantation.
Farges O; Samuel D; Bismuth H
Transplant Proc; 1994 Oct; 26(5):2676-8. PubMed ID: 7940838
[No Abstract] [Full Text] [Related]
25. Incidence and patterns of rejection using different induction therapies in liver transplant recipients.
Elkashab M; Reizig M; Greig PD; Cameron R; Phillips MJ; Chung S; Cattral M; Levy G
Transplant Proc; 1994 Oct; 26(5):2669-71. PubMed ID: 7940835
[No Abstract] [Full Text] [Related]
26. De novo cancer in transplant recipients.
Kim MS; Kim SI; Kim YS; Oh CK; Park K
Transplant Proc; 1996 Jun; 28(3):1651-2. PubMed ID: 8658822
[No Abstract] [Full Text] [Related]
27. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
[No Abstract] [Full Text] [Related]
28. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
[No Abstract] [Full Text] [Related]
29. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
[No Abstract] [Full Text] [Related]
30. Role of cyclosporine rescue therapy in steroid resistant rejections.
Sharma RK; Elhence R; Kher V; Gupta A; Kumar A; Bhandari M; Agrawal S
Transplant Proc; 1994 Oct; 26(5):2556-7. PubMed ID: 7940789
[No Abstract] [Full Text] [Related]
31. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
[No Abstract] [Full Text] [Related]
32. Combined high and low dosing of OKT3 for treatment of rejection episodes in renal transplants.
Schweizer RT; Bartus S; Hull D; Perdrizet G; Roper L
Transplant Proc; 1994 Dec; 26(6):3141. PubMed ID: 7998094
[No Abstract] [Full Text] [Related]
33. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy.
Faull RJ; Bannister KM; Russ GR; Mathew TH; Clarkson AR
Transplant Proc; 1999; 31(1-2):1155-6. PubMed ID: 10083516
[No Abstract] [Full Text] [Related]
34. Successful therapy of chronic renal allograft failure by enhanced immunosuppression.
Kliem V; Tiroke T; Ehlerding G; Eberhard O; Behrend M; Frei U; Koch KM; Pichlmayr R; Brunkhorst R
Transplant Proc; 1998 Jun; 30(4):1207-9. PubMed ID: 9636490
[No Abstract] [Full Text] [Related]
35. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.
Wiener Y; Nakhleh RE; Lee MW; Escobar FS; Venkat KK; Kupin WL; Mozes MF
Clin Transplant; 1997 Jun; 11(3):157-62. PubMed ID: 9193835
[TBL] [Abstract][Full Text] [Related]
36. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
[No Abstract] [Full Text] [Related]
37. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
[No Abstract] [Full Text] [Related]
38. Predictors of improved outcome in second pediatric renal transplant recipients.
Moss A; Almond PS; Matas AJ; Gillingham K; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 1):597. PubMed ID: 8438429
[No Abstract] [Full Text] [Related]
39. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
VanderWerf BA
Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
[No Abstract] [Full Text] [Related]
40. Ganciclovir treatment for cytomegalovirus infections in renal transplant recipients.
Buturović-Ponikvar J; Kandus A; Malovrh M; Ponikvar R; Kveder R
Transplant Proc; 1992 Oct; 24(5):1921-3. PubMed ID: 1329287
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]